JB Capital LLC Boosts Stake in AbbVie Inc. $ABBV

JB Capital LLC lifted its position in AbbVie Inc. (NYSE:ABBV) by 269.7% in the fourth quarter, Holdings Channel reports. The firm owned 16,913 shares of the company’s stock after acquiring an additional 12,338 shares during the period. JB Capital LLC’s holdings in AbbVie were worth $3,864,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Evolution Wealth Management Inc. purchased a new stake in AbbVie in the second quarter valued at approximately $26,000. Chelsea Counsel Co. purchased a new position in shares of AbbVie during the third quarter worth approximately $26,000. Westend Capital Management LLC acquired a new position in shares of AbbVie in the 4th quarter valued at $29,000. Texas Capital Bancshares Inc TX acquired a new position in shares of AbbVie in the 3rd quarter valued at $31,000. Finally, Caitlin John LLC purchased a new stake in AbbVie in the 3rd quarter valued at $33,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling

In other news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is currently owned by insiders.

AbbVie Price Performance

NYSE:ABBV opened at $208.79 on Friday. The firm has a market cap of $369.17 billion, a price-to-earnings ratio of 88.47, a price-to-earnings-growth ratio of 0.73 and a beta of 0.38. The firm’s fifty day moving average price is $221.58 and its 200 day moving average price is $224.47. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. AbbVie’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Analysts Set New Price Targets

ABBV has been the subject of a number of recent research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. UBS Group reduced their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a report on Thursday, February 5th. Piper Sandler increased their target price on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Finally, Barclays started coverage on AbbVie in a research report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.15.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.